The global occlusion devices market size is expected to reach USD 4.62 Billion in 2028 and register a CAGR of 5.2% over the forecast period, according to the latest report by Reports and Data. Usage of occlusion devices to prevent blood clots effectively is set to drive market revenue growth. If blood clots are not prevented on time, these may lead to stroke. Also, occlusion devices are extensively used in various applications such as cardiology neurology, oncology and others.
Rising demand for occlusion devices from hospitals, diagnostic centers & surgical centers, and ambulatory care centers will enhance market growth during the forecast period. These devices are helpful in maintaining the proper function of a patient’s body after he/she has suffered from peripheral vascular diseases or other severe disorders.
Rising number of surgeries associated with cardiological and neurological disorders has increased demand for occlusion devices, which, in turn, would help the market to grow at a fast pace. Occlusion devices are nowadays being used in the field of oncology. Embolization helps to prevent blood flow to a tumor and minimizes blood loss at the time of surgeries.
However, high cost of these devices may hamper growth of the occlusion devices market in the upcoming years. Additionally, stringent government rules and regulations revolving around the launch of new occlusion devices and expensive nature of complex surgical procedures are also set to hinder market growth. Coupled with this, lack of advanced healthcare facilities in underdeveloped countries is anticipated to affect the occlusion devices market growth negatively in the near future.
Top Companies Profiled in the Report Include:
Abbott Laboratories
Braun Melsungen AG
Boston Scientific Corporation
Cardinal Health
Edwards Lifesciences Corporation
